

Osiris Therapeutics

[View the current Osiris Therapeutics Page on BioPortfolio.com](http://www.bioportfolio.com/bi corporate/7942-Osiris+Therapeutics.html)

(<http://www.bioportfolio.com/bi corporate/7942-Osiris+Therapeutics.html>)

Contact Details:

2001 Aliceanna Street

Baltimore

MD

21231

United States of America

Tel: 410 522 5005

Fax: 410 522 6999

Email: osiris@Osiris.com

Leading the way to a better tomorrow Osiris Therapeutics, Inc. is a company founded to commercialize stem cell products from adult bone marrow. These stem cells have demonstrated the ability to repair different types of tissues. The next revolution in medical care Osiris Therapeutics is commercializing products from a readily available and non-controversial source – adult bone marrow. These stem cells have demonstrated the ability to repair different types of tissue and offer a very real opportunity to develop revolutionary new treatments for certain disease processes including autoimmune disorders, heart attacks and arthritis. Osiris' technology is based on the pioneering work of Dr. Arnold Caplan and his colleagues at Case Western Reserve University. They showed that Mesenchymal Stem Cells (MSCs) can engraft and selectively differentiate, based on the tissue environment, to such lineages as muscle, bone, cartilage, marrow stroma, tendon and fat. Due to their cellular origin and phenotype, these cells do not provoke an immune response, allowing for the development of products derived from unrelated human donors.

Recent Publications by Osiris Therapeutics:



- [Treatment of inflammatory diseases with mesenchymal stem cells.](#)
Human mesenchymal stem cells (hMSCs) are rare progenitor cells present in... 18th June, 2009
Osiris Therapeutics, Inc., 7015 Albert Einstein Drive, Columbia, MD 21046,- Inflamm Allergy Drug Targets. 2009 Jun;8(2):110-23.
- [Purification of sequence-specific DNA-binding proteins by affinity chromatography.](#)
The affinity chromatography procedure described in this unit uses DNA... 17th June, 2008
Osiris Therapeutics, Baltimore, Maryland, USA.- Curr Protoc Protein Sci. 2001 May;Chapter 9:Unit 9.6.
([DOI Direct Link](#))
- [Immunologic consequences of multiple, high-dose administration of allogeneic mesenchymal stem cells to baboons.](#)

- Mesenchymal stem cells (MSCs) express low immunogenicity and demonstrate...* 19th June, 2007
Osiris Therapeutics, Inc., Baltimore, MD, USA.- *Cell Transplant*. 2006;15(8-9):711-21.
- [Donor hematopoietic cells from transgenic mice that express GFP are immunogenic in immunocompetent recipients.](#)
OBJECTIVE: To study the immunogenicity of hematopoietic cells marked with... 31st December, 2005
Osiris Therapeutics Inc., 2001 Aliceanna Street, Baltimore, MD 21231, USA.- *Hematology*. 2005 Aug;10(4):289-95. ([DOI Direct Link](#))
 - [T cell responses to allogeneic human mesenchymal stem cells: immunogenicity, tolerance, and suppression.](#)
Human mesenchymal stem cells (MSCs) were evaluated for their ability to... 28th October, 2005
Osiris Therapeutics, Inc., 2001 Aliceanna Street, Baltimore, MD 21231,- *J Biomed Sci*. 2005;12(1):47-57. ([DOI Direct Link](#))
 - [A comparative study of biphasic calcium phosphate ceramics for human mesenchymal stem-cell-induced bone formation.](#)
For the repair of bone defects, a tissue engineering approach would be to... 21st June, 2005
Osiris Therapeutics,- *Biomaterials*. 2005 Jun;26(17):3631-8. ([DOI Direct Link](#))
 - [Feridex labeling of mesenchymal stem cells inhibits chondrogenesis but not adipogenesis or osteogenesis.](#)
Magnetic resonance (MR) tracking of superparamagnetic iron oxide... 1st April, 2005
Osiris Therapeutics Inc., Baltimore, MD, USA.- *NMR Biomed*. 2004 Nov;17(7):513-7. ([DOI Direct Link](#))
 - [Human mesenchymal stem cells modulate allogeneic immune cell responses.](#)
Mesenchymal stem cells (MSCs) are multipotent cells found in several adult... 4th March, 2005
Osiris Therapeutics, 2001 Aliceanna St, Baltimore, MD 21231, USA.- *Blood*. 2005 Feb 15;105(4):1815-22. Epub 2004 Oct 19. ([DOI Direct Link](#))
 - [Mesenchymal stem cells and their potential as cardiac therapeutics.](#)
Mesenchymal stem cells (MSCs) represent a stem cell population present in... 16th December, 2004
Osiris Therapeutics, Inc., 2001 Aliceanna St, Baltimore, MD 21231, USA.- *Circ Res*. 2004 Jul 9;95(1):9-20. ([DOI Direct Link](#))
 - [Mesenchymal stem cells: clinical applications and biological characterization.](#)
Mesenchymal stem cells (MSCs) have been isolated from bone marrow,... 22nd October, 2004
Osiris Therapeutics Inc., 2001 Aliceanna Street, Baltimore, MD 21231, USA.- *Int J Biochem Cell Biol*. 2004 Apr;36(4):568-84. ([DOI Direct Link](#))
 - [Biology and clinical applications of mesenchymal stem cells.](#)
Stem cell populations are found in most adult tissues and, in general,... 1st May, 2004
Osiris Therapeutics Inc., 2001 Aliceanna St., Baltimore, MD 21231, USA.- *Birth Defects Res C Embryo Today*. 2003 Aug;69(3):250-6. ([DOI Direct Link](#))
 - [Stem cell therapy in a caprine model of osteoarthritis.](#)
OBJECTIVE: To explore the role that implanted mesenchymal stem cells may... 15th January, 2004
Osiris Therapeutics, Baltimore, Maryland 21231, USA.- *Arthritis Rheum*. 2003 Dec;48(12):3464-74. ([DOI Direct Link](#))
 - [Allogeneic mesenchymal stem cells regenerate bone in a critical-sized canine segmental defect.](#)
BACKGROUND: Mesenchymal stem cells from adult bone marrow are multipotent... 3rd December, 2003
Osiris Therapeutics,- *J Bone Joint Surg Am*. 2003 Oct;85-A(10):1927-35.

Press Releases on Osiris Therapeutics:

U.S. Food And Drug Administration (FDA) Grants Traditional Approval for INTELENCE(R) (etravirine)	25th November, 2009	Tibotec Therapeutics	- Severe, potentially life-threatening, and fatal skin reactions have been reported in patients taking INTELENCE. These include cases of Stevens-Johnson syndrome, toxic
Reportlinker Adds Intranasal Drug Delivery - US Market Trends & Analysis	25th November, 2009	Reportlinker	NEW YORK, Nov. 25 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue: Intranasal Drug Delivery - US Market Trends & Analysis http://www
Reportlinker Adds Veterinary Vaccines - A World Market Analysis	25th November, 2009	Reportlinker	NEW YORK, Nov. 25 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue: Veterinary Vaccines - A World Market Analysis http://www.reportlinker.com
Reportlinker Adds Prostate Cancer Therapeutics - a Global Market Perspective	25th November, 2009	Reportlinker	NEW YORK, Nov. 25 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue: Prostate Cancer Therapeutics - A Global Market Perspective http://www
Reportlinker Adds Regenerative Medicine - Global Market Trends	25th November, 2009	Reportlinker	NEW YORK, Nov. 25 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue: Regenerative Medicine - Global Market Trends http://www.reportlinker.com

BioNews Results for Osiris Therapeutics



- [Stem cell therapy tried on AGH heart attack patients \[The Pittsburgh Tribune-Review\]](#)
Pharmacy Choice: Nov 20 2009 10:16PM Matching: osiris therapeutics
- [US holds 60% share of the global stem cell market, key players include Osiris Therapeutics.](#)
PR inside: Nov 18 2009 5:30PM Matching: osiris therapeutics
- [Global Stem Cell and Advanced Technologies Market](#)
Mindbranch: Nov 14 2009 6:13AM Matching: osiris therapeutics
- [MarketsandMarkets Publishes Stem Cells Market Research Report](#)
US PRWire: Nov 12 2009 8:56AM Matching: osiris therapeutics
- [Reportlinker Adds Global Stem Cell and Advanced Technologies Market](#)
Entrepreneur.com: Nov 11 2009 3:50PM Matching: osiris therapeutics
- [Reportlinker's new report on the global stem cell and advanced technologies market](#)

- News-Medical.Net: Nov 11 2009 7:01AM Matching: osiris therapeutics*
- [Reportlinker Adds Global Stem Cell and Advanced Technologies Market Interest!ALERT: Nov 10 2009 8:51PM Matching: osiris therapeutics](#)
 - [Reportlinker Adds Global Stem Cell and Advanced Technologies Market TMC Net: Nov 10 2009 3:57PM Matching: osiris therapeutics](#)
 - [Reportlinker Adds Global Stem Cell and Advanced Technologies Market PR Newswire via Yahoo!: Nov 10 2009 3:13PM Matching: osiris therapeutics](#)
 - [Bharat Book Bureau: Global Stem Cell and Advanced Technologies Market RBC Dain Rauscher: Nov 10 2009 10:58AM Matching: osiris therapeutics](#)
 - [Bharat Book Bureau: Global Stem Cell and Advanced Technologies Market TradingMarkets: Nov 10 2009 10:32AM Matching: osiris therapeutics](#)
 - [Global Stem Cell and Advanced Technologies Market PR inside: Nov 10 2009 5:22AM Matching: osiris therapeutics](#)
 - [US Holds 60% Share Of The Global Stem Cell Market, Key Players Include Osiris Therapeutics, Stem Tronix Inc.. OfficialSpin: Nov 9 2009 8:43AM Matching: osiris therapeutics](#)
 - [Osiris to get US\\$ 15 mn milestone payment from NuVasive for sale of Osteocel business PharmaBiz: Nov 6 2009 12:19PM Matching: osiris therapeutics](#)
 - [MarketsandMarkets: Global Stem Cell and Advanced Technologies Market Worth US\\$ 88.3 Billion by 2014 PR-USA.net: Nov 6 2009 9:33PM Matching: osiris therapeutics](#)

Osiris Therapeutics Clinical Trials:



- [Safety and Efficacy Study of Adult Human Mesenchymal Stem Cells to Treat Acute GVHD.](#)

Osiris Therapeutics Patents:



- 7514074- [Cardiac muscle regeneration using mesenchymal stem cells](#)
- 6149906- [Antigen presenting cells of the adipocyte lineage](#)
- 6174333- [Biomatrix for soft tissue regeneration using mesenchymal stem cells](#)
- 6225119- [Production of megakaryocytes by the use of human mesenchymal stem cells](#)
- 6239157- [Inhibition of osteoclastogenesis](#)
- 6255112- [Regulation of hematopoietic stem cell differentiation by the use of human mesenchymal stem cells](#)
- 6261549- [Human mesenchymal stem cells from peripheral blood](#)
- 6281012- [Method of preparing suppressor T cells with allogeneic mesenchymal stem cells](#)

- 6322784- [Adipogenic differentiation of human mesenchymal stem cells](#)
- 6030836- [Vitro maintenance of hematopoietic stem cells](#)
- 6022540- [Ligands that modulate differentiation of mesenchymal stem cells](#)
- 5643736- [Monoclonal antibodies for human osteogenic cell surface antigens](#)
- 5811094- [Connective tissue regeneration using human mesenchymal stem cell preparations](#)
- 5827740- [Adipogenic differentiation of human mesenchymal stem cells](#)
- 5837539- [Monoclonal antibodies for human mesenchymal stem cells](#)
- 5908782- [Chemically defined medium for human mesenchymal stem cells](#)
- 5942225- [Lineage-directed induction of human mesenchymal stem cell differentiation](#)
- 5965436- [Method of isolating mesenchymal stem cells associated with isolated megakaryocytes by isolating megakaryocytes](#)
- 6010696- [Enhancing hematopoietic progenitor cell engraftment using mesenchymal stem cells](#)
- 6328960- [Mesenchymal stem cells for prevention and treatment of immune responses in transplantation](#)
- 6342370- [Human slit polypeptide and polynucleotides encoding same](#)
- 6797269- [Mesenchymal stem cells as immunosuppressants](#)
- 6835377- [Osteoarthritis cartilage regeneration](#)
- 6863900- [Regeneration and augmentation of bone using mesenchymal stem cells](#)
- 6875430- [Mesenchymal stem cells for prevention and treatment of immune responses in transplantation](#)
- 7029666- [Uses for non-autologous mesenchymal stem cells](#)
- 7101704- [Antigen presenting mesenchymal stem cells](#)
- 7153500- [Production of megakaryocytes by the use of human mesenchymal stem cells](#)
- 7491388- [Uses of fibroblasts or supernatants from fibroblasts for the suppression of immune responses in transplantation](#)
- 6761887- [Alginate layer system for chondrogenic differentiation of human mesenchymal stem cells](#)
- 6709864- [Adipogenic differentiation of human mesenchymal stem cells](#)
- 6355239- [Uses for non-autologous mesenchymal stem cells](#)
- 6358702- [Polynucleotides encoding human Hox C10](#)
- 6368636- [Mesenchymal stem cells for prevention and treatment of immune responses in transplantation](#)
- 6379953- [Ligands that modulate differentiation of mesenchymal stem cells](#)
- 6387367- [Human mesenchymal stem cells](#)
- 6387369- [Cardiac muscle regeneration using mesenchymal stem cells](#)
- 6541024- [Regeneration and augmentation of bone using mesenchymal stem cells](#)
- 6685936- [Suppressor cells induced by culture with mesenchymal stem cells for treatment of immune responses in transplantation](#)
- 5486359- [Human mesenchymal stem cells](#)

BioCorporate Profiles - upgrade to a full profile

BioPortfolio's BioCorporate full profiles offers your organization the opportunity to increase internet traffic to your corporate web site and enhance awareness of your business, technology, products and services. BioCorporate profiles are dynamic and are updated weekly with new information sourced from core information resources: publications, clinical trials, patents and global news.

Why you should upgrade your BioPortfolio BioCorporate profile:

- the ability to amend and add information on products and services to your profile using a membership username and password
- the option to add a corporate logo

- the creation of high value URL links back to your organization's website which will improve search engine ranking - resulting in increased site traffic
- the option have your press releases published on BioPortfolio and distributed via our BioNewsCast service
- an enhanced BioCorporate profile will also improve your exposure on BioPortfolio's related service InDepth and GeneDB

The annual cost is \$995.00 for established organizations and \$495.00 for organizations less than 12 months old.

Resources from the [NCBI](#) used in this document, [NCBI's standard disclaimer applies](#).

Nothing in this document should be used in place of personal medical advice from your own qualified medical practitioner. See BioPortfolio.com [User Agreement](#)

Send comments and feedback to:

Peter Barfoot Managing Director, BioPortfolio Ltd.

UK Tel: (+44) 1300 321501

USA Voicemail and Fax: (+1) 415 680 2472

[Peter Barfoot peter.barfoot@bioportfolio.com](mailto:peter.barfoot@bioportfolio.com)

All rights reserved. All other trademarks recognized.

BioPortfolio Limited is registered in England & Wales at Stafford House, 10 Prince of Wales Road, Dorchester, Dorset, DT1 1PW, UK. No.3312883 VAT No. GB 744 6483 10

Copyright 1997-2009 - BioPortfolio Limited.

